Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events
FCARH143, a fully human BCMA-directed CAR-T cell therapy, shows remarkable long-term efficacy and manageable safety profile in heavily pretreated relapsed/refractory multiple myeloma patients over 5 years.
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p
Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.
Elevated proinflammatory cytokines combined with low peripheral blood counts early after CD19 CAR-T cell infusion correlate with poor treatment response and severe toxicity in relapsed/refractory B-ALL, highlighting inflammation as a key mo
A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.
The ZUMA-8 phase 1 study evaluates the safety and efficacy of brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, in relapsed/refractory CLL, showing promising response rates and manageable safety profiles, especially in patients
This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.
The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML,
Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.
An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.
This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advance
Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell ly
Eltrombopag combined with immunosuppressive therapy shows promising efficacy in severe aplastic anemia, especially in relapsed/refractory pediatric patients, with over half achieving hematologic responses and transfusion independence, suppo
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.
Open language-specific specialty feeds and department pages.